Ecallantide: A plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema

Drugs of Today

Volumn 46, Issue 8, 2010, Pages 547-555

  Stolz, Leslie E ^a   Horn, P T ^a  

^a Dyax Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CYTOCHROME P450; ECALLANTIDE; PLACEBO; PLASMA KALLIKREIN; ENZYME INHIBITOR; PEPTIDE;

ACUTE DISEASE; ANALGESIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ERYTHEMA; FATIGUE; FLUID THERAPY; FLUSHING; HUMAN; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE URTICARIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; PAIN; PARTIAL THROMBOPLASTIN TIME; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SNEEZING; THORAX PAIN; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WHEEZING; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; ENZYMOLOGY; EVIDENCE BASED MEDICINE; METABOLISM; RISK ASSESSMENT; TREATMENT OUTCOME;

ANGIOEDEMAS, HEREDITARY; DRUG HYPERSENSITIVITY; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; PEPTIDES; PLASMA KALLIKREIN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79952111523     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.8.1507205     Document Type: Review

References (28)

1. Gompels, M.M., Lock, R.J., Abinun, M. et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 2005, 139(3): 379-94.
2. Zuraw, B.L. Clinical practice. Hereditary angioedema. N Engl J Med 2008, 359(10): 1027-36.
3. Goring, H.D., Bork, K., Spath, P.J., Bauer, R., Ziemer, A., Hintner, H., Wuthrich, B. [Hereditary angioedema in the German-speaking region]. Hautarzt 1998, 49(2): 114-22.
4. Agostoni, A., Cicardi, M. Hereditary and acquired C1- inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine 1992, 71(4): 206-15.
5. Bork, K., Meng, G., Staubach, P., Hardt, J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 2006, 119(3): 267-74. (Pubitemid 43255068)
6. Agostoni, A., Aygoren-Pursun, E., Binkley, K.E. et al. Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004, 114(3): S51-131.
7. Bork, K., Staubach, P., Eckardt, A.J., Hardt, J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006, 101(3): 619-27. (Pubitemid 43340941)
8. Bork, K., Hardt, J., Schicketanz, K.-H., Ressel, N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003, 163(10): 1229-35. (Pubitemid 36613077)
9. Bork, K., Siedlecki, K., Bosch, S., Schopf, R.E., Kreuz, W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000, 75(4): 349-54. (Pubitemid 30187107)
10. Craig, T., Riedl, M., Dykewicz, M.S. et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009, 102(5): 366-72.
11. Donaldson, V.H., Evans, R.R. A biochemical abnormality in hereditary angioneurotic edema, absence of serum inhibitor of C1-esterase. Am J Med 1963, 35: 37-44.
12. Kaplan, A.P., Joseph, K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104(3): 193-204.
13. Davis, A.E.3rd. The pathophysiology of hereditary angioedema. Clin Immunol 2005, 114(1): 3-9.
14. Keating, G.M. Human C1-esterase inhibitor concentrate (Berinert). BioDrugs 2009, 23(6): 399-406.
15. Thompson, C.A. FDA approves kallikrein inhibitor to treat hereditary angioedema. Am J Health Syst Pharm 2010, 67(2): 93.
16. Zuraw, B., Yasothan, U., Kirkpatrick, P. Ecallantide. Nat Rev Drug Discov 2010, 9(3): 189-190.
17. Bernstein, J.A., Qazi, M. Ecallantide: Its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 2010, 6(1): 29-39.
18. Williams, A.H., Baird, L.G. DX-88 and HAE: A developmental perspective. Transfus Apher Sci 2003, 29(3): 255-8.
19. Ley, A.C., Markland, W., Ladner, R.C. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Mol Divers 1996, 2(1-2): 119-24. (Pubitemid 126817074)
20. Markland, W., Ley, A.C., Ladner, R.C. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996, 35(24): 8058-67.
21. Levy, J.H., O'Donnell, P.S. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006, 15(9): 1077-90. (Pubitemid 44314659)
22. Advisory Committee Briefing Document: Kalbitor® (ecallantide) for acute attacks of hereditary angioedema (BLA 125277). 2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM170334.pdf. Accessed on: March 12, 2010.
23. Vernon, M.K., Rentz, A.M., Wyrwich, K.W., White, M.V., Grienenberger, A. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 2009, 18(7): 929-39.
24. Cicardi, M., Levy, R.J., McNeil, D.L. et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010, 363(6): 523-31.
25. Levy, R.J., Lumry, W.R., McNeil, D.L. et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010, 104(6): 523-9.
26. Berinert (C1-Esterase Inhibitor [Human]) [US package insert]. Marburg, Germany: CSL Behring; November 2009. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ FractionatedPlasmaProducts/UCM186268.pdf.
27. KALBITOR® [package insert]. Cambridge, MA: Dyax Corp.; December 2009. Available at: http://www.kalbitor.com/pdf/KalbitorFullPrescribingInformation. pdf.
28. Sampson, H.A., Munoz-Furlong, A., Campbell, R.L. et al. Second symposium on the definition and management of anaphylaxis: Summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117(2): 391-7. (Pubitemid 43190153)